" />
t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 b3a2 fusion transcript/control transcript.reduction
to 0.1% post treatment:PrThr:Pt:Bld/Tiss:Ord:Molgen - CISMeF
T(9;22)(q34.1;q11)(ABL1,BCR) b2a2 b3a2 fusion transcript/control transcript.reduction
to 0.1% post treatment:PrThr:Pt:Bld/Tiss:Ord:MolgenLOINC code
Preferred Label : t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 b3a2 fusion transcript/control transcript.reduction
to 0.1% post treatment:PrThr:Pt:Bld/Tiss:Ord:Molgen;
LOINC status : ACTIVE;
LOINC display name : t(9;22)(q34.1;q11)(ABL1,BCR) b2a2 b3a2 fusion transcript/control transcript.reduction
to 0.1% post treatment Molgen Ql (Bld/Tiss);
LOINC long common name : BCR-ABL1 p210 Major Molecular Response (MMR) [Presence] in Blood or Tissue by Molecular
genetics method --post treatment;
LOINC short name : t(ABL1,BCR)p210/cntrl.0.1% p Tx Bld/T Ql;
LOINC description : Patient's with CML and undergoing tyrosine kinase inhibitor (TKI) therapy may be monitored
to assess their treatment response (reduction in BCR-ABL1 transcripts) to therapy.
A major molecular response (MMR) occurs when the ratio of BCR-ABL1 transcripts to
control gene is less than or equal to 0.1% according to the International Scale (IS),
a consensus standardized measurement scale intended to allow direct comparison of
BCR-ABL1 major breakpoint (b2a2, b3a2) RNA levels in any laboratory adopting its use.
Studies have demonstrated that achieving MMR within 18 months following TKI therapy
is associated with a minimal risk of progression at 84 months (NCCN Guidelines CML,
2013).;
Has challenge